Aaron Schuchart - 01 Jun 2021 Form 4 Insider Report for LUMOS PHARMA, INC.

Role: Chief Business Officer
Signature: /s/ Ryan Trytten, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 01 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 03 Jun 2021, 16:52:33 UTC
Previous filing: 28 May 2021
Next filing: 13 Aug 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LUMO	Stock Option (Right to Buy)	Award	$0	+7,805		$0.000000	7,805	01 Jun 2021	Common Stock	7,805	$10.13	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant to the Reporting Person of a stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on July 1, 2021, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. The option expires ten years after the date of grant.

Content

Grant to the Reporting Person of a stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). The option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on July 1, 2021, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. The option expires ten years after the date of grant.